New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
12:47 EDTVRX, AGNAllergan slides question Valeant growth, disclosures, says BMO Capital
BMO Capital says Allergan (AGN) issued new slides today calling into question Valeant's (VRX) disclosures and growth. The firm finds the slides "interesting," and says Allergan management last week noted that its current business "has never been stronger." BMO thinks investors should own Allergan, and sees the upcoming Q2 results as a potential catalyst. The firm has an Outperform rating on the name with a $202 price target.
News For AGN;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 27, 2015
05:40 EDTAGNTeva to acquire Allergan Generics for transaction valued at $40.5B
05:28 EDTAGNTeva withdraws proposal to acquire Mylan
Teva (TEVA) announced that it has withdrawn its cash and stock proposal to acquire all of the outstanding ordinary shares of Mylan (MYL) and Teva does not intend to continue to pursue a transaction with Mylan at this time. Teva’s decision to terminate the proposal to acquire Mylan follows announcement that Teva has entered into a definitive agreement with Allergan (AGN) to acquire Allergan Generics. Teva CEO Erez Vigodman commented, “We continue to believe that a combination of Teva and Mylan would have made sense for our companies, our respective stockholders and the healthcare industry as a whole. However, despite our clear commitment to consummating a transaction, and our conviction that we ultimately would have succeeded in acquiring Mylan, we believe we have an even greater opportunity to create compelling, sustainable value for Teva’s stockholders through our transaction with Allergan – and we acted quickly to seize the opportunity. Our agreement with Allergan will reinforce Teva’s strategy to create an even stronger business model in the industry and will position us well to grow the business and better serve our customers and patients.” Teva intends to review its options with respect to its ownership of approximately 4.6% of the outstanding ordinary shares of common stock of Mylan.
July 26, 2015
18:22 EDTAGNMedia reports say Teva to buy Allergan unit as it looks beyond Mylan
Subscribe for More Information
12:39 EDTAGNAllergan to acquire Naurex, plans research collaboration with Naurex spinoff
Subscribe for More Information
12:30 EDTAGNTeva nears deal to buy Allergan generics unit for $40.5B, Bloomberg says
Teva (TEVA) is nearing a deal to buy Allergan's (AGN) generic drug unit for roughly $40.5B and an agreement could be announced as early as Monday, reports Bloomberg, citing people familiar with the matter. Sources said Teva also plans to withdraw its bid for Mylan (MYL) as soon as Monday. Reference Link
12:17 EDTAGNTeva to cancel Mylan bid, plans offer for Allergan generics unit, Bloomberg says
Subscribe for More Information
July 24, 2015
18:36 EDTAGNAllergan considers split into two businesses, Bloomberg reports
Subscribe for More Information
18:25 EDTAGNAllergan considering breakup of company, Bloomberg reports
Allergan is reportedly working with advisors and leaning towards a sale or spinoff of generics, Bloomberg added.
07:06 EDTVRXValeant price target raised to $285 from $255 at UBS
Subscribe for More Information
06:51 EDTVRXValeant price target raised to $290 from $250 at JPMorgan
JPMorgan analyst Chris Schott raised his price target for Valeant Pharmaceuticals to $290 citing the company's "very strong" Q2 results. Schott sees further upside to estimates and reiterates an Overweight rating on the stock.
July 23, 2015
12:12 EDTVRXValeant beats RBC as biggest Canadian company by market value, Bloomberg says
Valeant (VRX) has surpassed Royal Bank of Canada (RY) as the largest Canadian company by market value on the Toronto Stock Exchange, Bloomberg reports. Valeant surged 4.5% to a total market value of C$111.3B at 11:21 AM in Toronto, beating the Royal Bank's C$108.3B market value, the report says. Reference Link
06:29 EDTVRXValeant raises FY15 cash EPS view to $11.5-$11.80 from $10.90-$11.20
Subscribe for More Information
06:26 EDTVRXValeant sees Q4 cash EPS $3.98-$4.18, consensus $3.49
Sees Q4 revenue $3.2B-$3.4B, consensus $3.03B.
06:25 EDTVRXValeant sees Q3 cash EPS $2.60-$2.70, consensus $2.86
Sees Q3 revenue $2.6B-$2.8B, consensus $2.74B.
06:24 EDTVRXValeant reports Q2 cash EPS $2.56, consensus $2.46
Subscribe for More Information
06:06 EDTVRXValeant raises FY15 cash EPS to $11.50-$11.80 from $10.90-$11.20
The increased EPS guidance reflects continued business outperformance and approval of IBS-D indication for Xifaxan. Raises FY15 total revenue to $10.7B-$10.4B from $10.4B-$10.6B. Sees FY15 Salix revenue $1.2B. Raises FY15 adjusted cash flow from operations to be greater than $3.2B from greater than $3.1B. Sees FY15 SSS organic growth of greater than 10% for 2H15.
06:05 EDTVRXValeant sees Q4 cash EPS $3.98-$4.18, revenue $3.2B-$3.4B
Subscribe for More Information
06:05 EDTVRXValeant sees Q3 cash EPS $2.60-$2.70, revenue $2.6B-$2.8B
Subscribe for More Information
06:04 EDTVRXValeant reports Q2 GAAP EPS (15c), Q2 cash EPS $2.56
Excluding negative impact of ForEx and Salix, cash EPS would have been $2.73. Reports Q2 total revenue $2.73B vs. $2.04B last year. Reports Q2 Product sales $2.70B vs. $1.99B last year. Reports Q2 SSS organic growth up 19%. Reports Q2 Salix revenue $313M.
July 21, 2015
10:01 EDTVRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use